Otonomy Announces Phase 3 Clinical Trial Plan for OTIPRIO™ in Otitis Externa Patients Based on Successful End-of-Phase 2 Review by FDA
April 18, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease
March 23, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 23, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Publication of OTIPRIO™ Phase 3 Clinical Trial Results in JAMA Otolaryngology
March 18, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO™ in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
March 03, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Commercial Availability of OTIPRIO™
March 02, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 02, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at J.P. Morgan Healthcare Conference
January 08, 2016 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Completes Enrollment in OTIPRIO(TM) Phase 2 Trial and Demonstrates Clinical Feasibility in Patients With Acute Otitis Externa
December 01, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Present at Piper Jaffray Healthcare Conference
November 24, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere's Disease
November 18, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 10, 2015 16:21 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...